A bolus-only GPIIb/IIIa inhibitors strategy seems to keep up with the anti-ischemic benefits, using the added advantage of reduced bleeding problems as well as the potential for lower cost and shortened amount of medical center stay
A bolus-only GPIIb/IIIa inhibitors strategy seems to keep up with the anti-ischemic benefits, using the added advantage of reduced bleeding problems as well as the potential for lower cost and shortened amount of medical center stay. In the simple trial (Bertrand et al 2006) (the first Discharge after Transradial Stenting of Coronary Arteries research), 1005 … Read more